The market is very promising and is constantly ushering in blockbuster financing!

【Pharmaceutical Network Industry News】Because the nervous system innervates the activities of various important organs of the human body, the application scope of neuromodulation technology is very extensive
.
Its applications mainly include deep brain stimulation (DBS), spinal cord stimulation (SCS), vagus nerve stimulation (VNS), etc.
, and treat diseases such as nervous system injury, motor dysfunction, chronic pain, spasticity, epilepsy, gastrointestinal and bladder dysfunction, peripheral vascular disease, cardiac ischemia, audiovisual impairment, and psychogenic diseases (such as depression, obsessive-compulsive disorder, tourette syndrome) and many other fields
。 In recent years, due to the intensification of the global aging trend and the shortage of effective neurological drugs, neuromodulation devices, as emerging technologies, have obvious efficacy in the treatment and alleviation of neurological and neurological diseases, and are attracting more and more capital attention
.
It is understood that since 2022, the field of neuromodulation has obtained several heavyweight financings
.
For example, in October, Hangzhou Shenluo Medical Technology Co.
, Ltd.
, an innovative company in the field of neuromodulation in China, has successfully completed nearly 100 million yuan of Series B financing
.
This round of financing was led by SDIC Venture Capital, and the old shareholder Boyuan Capital continued to make additional investment
.
The financing funds will be used for new product research and development, clinical research, registration applications and chip iteration
.
Founded in 2018, Shinwoo focuses on the independent research and development and production of medical devices in the field of implantable neuroregulation, and is committed to improving the quality of life
of more refractory patients by continuing to provide doctors and patients with more advanced and effective treatment methods.
At present, Shinwoo is developing neuromodulation products with different technical paths and different application scenarios, and all directions are progressing smoothly
.
In July, Midapeth, a company dedicated to the development of implantable or wearable neuromodulation therapy solutions for digestive tract systems, especially functional gastrointestinal diseases and metabolic diseases, announced the completion of tens of millions of yuan in Series A+ financing, exclusively invested
by Sycamore Tree Capital.
Prior to this, Midapest has completed two rounds of financing, with investors including Proxima Venture Capital, Datay Capital and other investment institutions and Pinchi Medical
.
In February, Jingyu Medical announced the completion of a RMB D+ round of financing of RMB 300 million, co-led by Sequoia China and Hillhouse Venture Capital.
In January, Jialiang Medical announced the completion of hundreds of millions of yuan in Series B financing
.
Combing through the list of innovative medical devices approved by the State Food and Drug Administration in recent years, it can be clearly found that there are currently more than ten neuromodulation-related technologies in China, and have shown great potential
for domestic substitution and innovative development.
It is worth mentioning that these breakthroughs are not limited to traditional technologies such as deep brain stimulation (DBS), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS), but have also made innovative breakthroughs
around the sacral nerve stimulation system (SNM).
On top of traditional technologies, neuromodulation companies including Jingyu Medical and Pinchi Medical have also made many innovative iterations
.
For example, on October 10, the "3.
0T magnetic resonance compatible rechargeable brain pacemaker" developed by Pinchi Medical completed the first clinical application after marketing in the First Affiliated Hospital of China University of Science and Technology, marking another progress
in the field of neuromodulation in China.
Industry analysts believe that compared with the global market, China's neuromodulation market is still in the early stage of development, and the competition pattern is good and not crowded
.
Therefore, neuromodulation technology will have a very broad development space in terms of indications, and its targeting, reversible, durable, and controllable treatment characteristics will also create more development space
for the subsequent market scale of this technology.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.